2018/12/13 – CRI Report

Research Report on Import of Pork and Pig Offal in China, 2019-2023

admin — Thu, 13 Dec 2018 02:22:37 +0000

Description
With the development of China’s economy and the improvement of living standards, the pork consumption in China is rising. China is the largest pork producer in the world. But pig breeding is costly in China because it is vulnerable to swine fever and the fluctuations in feed prices, which makes it difficult for the pork output to grow steadily. Meanwhile, the residents in some parts of the country like eating pig offal. Therefore, the overall import volume of pork and pig offal show an upward trend.
The Chinese government has strict inspection and quarantine policies on the import of pork products. In Nov. 2018, only 16 countries or regions including the U.S., Canada, Brazil, Chile and Mexico were allowed to export pork products to China. The Chinese government has set no import quota for the pork products from these countries, which means that import companies only need to pay the tariffs and value-added taxes. Thanks to the Sino-Chilean free trade agreement, China gives special privilege to the import of Chilean pork. When importing Chilean pork products such as bone-in pork and deboned pork, a Chinese enterprise only needs to pay 11% value-added tax on the import value. On the pork imports from the other countries, China levies tariffs and value-added taxes according to product type. Relatively speaking, the taxes on bone-in pork and deboned pork are lighter while the taxes on deboned pickled pork are heavier.
In 2017, the import volume of pork in China was about 1,217,000 tons, lower than that in 2016 but higher than that from 2013 to 2015. From 2013 to 2017, the annual import value of pork in China all exceeded USD 1 billion. In 2017, it was USD 2.22 billion, lower than that in 2016. The decline was mainly caused by the shrinking import volume. As the major sources of China’s pork imports, in 2017, Spain, Germany, the U.S., Canada, Denmark and the Netherlands exported 961,000 tons of pork in total to China, contributing about 80% to China’s pork imports.
As the residents in some parts of China like eating pig offal, China also imports a large quantity of pig offal every year. In 2017, the import volume of pig offal in China was about 1,236,000 tons, exceeding that of pork. As the major sources of China’s pig offal imports, in 2017, the U.S., Denmark, Germany, Spain, Canada and the Netherlands exported 1,059,000 tons of pig offal in total to China, contributing more than 80% to China’s pig offal imports.
In 2017, as the third largest source of China’s pork imports, the U.S. exported about 170,000 tons of pork to China, accounting for 14% of China’s pork imports; as the largest source of China’s pig offal imports, the U.S. exported about 416,000 tons of pig offal to China, accounting for about one-third of China’s pig offal imports. In 2018, with the escalation of the Sino-U.S. trade war, U.S. exports of pork and pig offal to China dropped significantly from 2017.
According to CRI’s analysis, China’s annual pork consumption is around 55 million tons, and is growing slowly in recent years. In 2017, the pork imports were less than 3% of the pork consumption. Rising pig breeding costs and stricter environmental policies have forced many small and medium-sized pig farms to close down, and swine fever occurs frequently. These factors discourage the growth of pork output in China. It is expected that from 2019 to 2023, the import volume of pork and pig offal in China will continue to rise, and China’s pork market will receive attention from the pig farmers and pork traders all over the world.

Topics Covered
– Chinese government’s policies on pork import
– Import volume of pork in China from 2013 to 2018
– Major sources of China’s pork imports
– Prices of homemade and imported pork in China
– Pork smuggling to China
– Major factors influencing pork import in China from 2019 to 2023
– Prospect of pork import in China from 2019 to 2023
– Impact of Sino-U.S. trade war on pork import in China

The post Research Report on Import of Pork and Pig Offal in China, 2019-2023 first appeared on CRI Report.

Research Report on Beef Import in China, 2019-2023

admin — Thu, 13 Dec 2018 02:22:34 +0000

Research Report on Beef Import in China

Topics Covered
– The Chinese government’s policies on beef import
– Beef import in China
– Major types of China’s beef imports
– Major sources of China’s beef imports
– Favorable and unfavorable factors influencing beef import in China
– Prospect of beef import in China, 2019-2023

Description
With the development of China’s economy and the improvement of living standards, the demand for beef in China is rising. The upward cattle breeding cost makes it difficult to sharply increase the beef output in China.

In response to the growing beef consumption, China is importing more beef. From 2013 to 2017, the beef output volume in China grew from 6,130,900 tons to 6,346,200 tons at a CAGR of only 0.9%, while the beef imports grew at a CAGR of nearly 24%.

The Chinese government’s policies on beef import include restrictions and incentives. On one hand, to control epidemics and support domestic beef industry, the Chinese government bans the import of cattle and cattle products from high-risk countries and regions. On the other hand, it signs trade agreements with some countries to cut the tariffs on beef imports and increase the beef supply in China.

The government is strict with the sources of beef imports. Only the countries and regions included in China Customs’ List of Meat Eligible for Export to China from Countries or Regions that Meet the Requirements of Assessment and Review can export beef to China. In Nov. 2018, the list included only 16 countries such as the U.S., Canada, Argentina, Chile and Uruguay.

The beef imported to China include chilled beef and frozen beef. Frozen beef has been the main stream of China’s beef imports. From 2013 to 2017, the proportion of frozen beef in China’s beef imports stayed above 96%. In 2017, this proportion reached about 99%.

China’s beef imports mainly come from Brazil, Australia, Uruguay, New Zealand and Argentina. In 2017, the five countries contributed more than 90% of both the import value and import volume of beef in China.

It was not until Jul. 2017 that U.S. beef was allowed to enter China. Therefore, U.S. beef sells badly in China, and can hardly compete with the beef from countries like Brazil and Australia. As U.S. beef, whether by volume or value, takes up a small proportion of China’s beef imports, the Sino-U.S. trade war has little impact on the export of U.S beef. to China.

According to CRI’s market research, China impose high tariffs and value-added tax on beef imports, and most countries in the world cannot legally export beef to China. Therefore, many enterprises smuggle beef to China. The smuggled beef mainly come from India and Brazil by water transport and road transport.

By water transport, the smuggled beef is directly shipped from India and Brazil to China’s coastal ports, and then distributed to all parts of the country. By road transport, the smuggled beef is transported via Hong Kong to Shenzhen, or entered China via the border between Vietnam and Guangxi.

In addition to the cheap beef from India and Brazil, Wagyu beef from Japan and other types of high-end beef are also smuggled. Smuggled beef and legally imported beef share similar end consumers, namely, households, catering enterprises and food processing enterprises.
It is expected that the import volume of beef in China will continue to grow from 2019 to 2023.

The post Research Report on Beef Import in China, 2019-2023 first appeared on CRI Report.

Investigation Report on China’s Loratadine Market, 2018-2022

admin — Thu, 13 Dec 2018 02:22:31 +0000

China’s Loratadine Market Overview

The incidences of common skin redness, itching and rashes and respiratory allergies are rising as China’s economy develops, the living environment and dietary structure change, and environmental pollution intensifies, which drives the growth of the antihistamine market.

As a second-generation antihistamine, Loratadine is a common H1 receptor antagonist used to relieve the symptoms of allergic rhinitis, eye itching and burning sensation, and the symptoms and signs of chronic urticaria, pruritic skin diseases and other allergic skin diseases. It can quickly relieve nose and eye allergies. Moreover, Loratadine has a low affinity for the H1 receptor of the central nervous system, and thus has hardly any side effect on the nervous system.

Developed by Schering-Plough which has been acquired by Bayer, Loratadine (trade name: Clarityne) was first launched in Belgium in 1988 and then sold in several European countries. In Apr. 1993, it was approved by the FDA to be marketed in the U.S. In Sept. 2002, it was launched in Japan. In November of the same year, the FDA approved Clarityne as a non-prescription drug.

According to CRI, in Jun. 1993, imported Loratadine tablets were approved to be sold in China under the trade name Clarityne. In 2005, the CFDA approved Clarityne as a non-prescription drug for its excellent effect and long-tested safety. Many Chinese companies have launched generic Loratadine products in the dosage forms of oral tablets, capsules, granules, syrup and compound preparation. The market competition is fierce but the brand-name drug still has great advantages. In 2017, Shanghai Schering-Plough Pharmaceutical Co., Ltd. and Schering-Plough occupied about 65% market share by sales value. But the market share of the brand-name drug showed a downward trend.

Loratadine has secured a place on the market by advantage of long-lasting and quick-acting effect and rare adverse reactions. However, with the increasing number of Loratadine manufacturers and intensifying competition on the market, the average price of Loratadine is declining.
It is expected that as the incidences of allergic diseases continue to increase, China’s Loratadine market will still have some growth potential in the next few years.

Topics Covered:
– Situation of allergic diseases in China
– Status of China’s Loratadine market
– Competition on China’s Loratadine market
– Prices of Loratadine in China
– Major factors influencing development of China’s Loratadine market
– Prospect of China’s Loratadine market from 2018 to 2022

The post Investigation Report on China’s Loratadine Market, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Recombinant Human Lutropin alfa Market, 2018-2022

admin — Thu, 13 Dec 2018 02:22:26 +0000

Description
According to the WHO’s estimate, infertility affects 15% to 20% of the global population. Survey data shows that in 2017, the incidence of infertility among married couples in China was 10%, more than double the 4.8% in 1984. As environmental pollution intensifies and the lifestyle changes, the incidence of infertility is increasing and infertility is increasingly prevalent among Chinese young people. About 15% to 20% women of childbearing age in China are troubled by infertility. As the biggest cause of female infertility in China, follicular dysplasia syndrome resulting from endocrine dysfunction accounts for over 40% of infertility cases. In addition to reasonable adjustments to menstrual period and etiological treatment, for fertilization, it is necessary to adopt an ideal solution to promote the development and maturation of follicles in clinical treatment.
Since 2015 when the Chinese government relaxed its family planning policy, sex hormone drugs have been growing rapidly, and the infertility treatment and IVF, an assisted reproductive technology (ART), have attracted much attention. In China’s end markets of ART and sex hormone drugs, macromolecular bioengineered drugs such as Recombinant Human Follitropin, Recombinant Follitropin Beta, Recombinant Human Chorionic Gonadotropin, and Human Lutropin alfa are taking the place of small-molecule chemicals.
Recombinant Human Lutropin alfa is a glycoprotein obtained by genetic engineering technique. It can combine with the luteinizing hormone/chorionic gonadotropin (LH/CG) receptor on the ovariole sheath (and granular layer) and the Leydig cell membrane. For women who lack luteinizing hormone and follicle-stimulating hormone (FSH) to ovulate, the use of LH can increase the level of estradiol secreted by the follicle and stimulate follicular development.
Merck Serono’s Recombinant Human Lutropin alfa (trade name: Luveris) was approved to be sold in China in 2008. In 2017, the sales value exceeded CNY 30 million. By the end of 2018, China’s Recombinant Human Lutropin alfa market is monopolized by Merck Serono. According to CRI’s analysis, multinational companies such as Merck Serono and Merck Sharp & Dohme dominate China’s fertility drug market. Meanwhile, Chinese companies such as Livzon Pharmaceutical Group Inc., GeneScience Pharmaceuticals Co., Ltd., Zhejiang Xianju Pharmaceutical Co., Ltd., Hybio Pharmaceutical Co., Ltd., and Chia Tai Tianqing Pharmaceutical Group Co., Ltd. are also launching generic drugs. It is expected that the pattern of China’s Recombinant Human Lutropin alfa market will change in the next few years.
In 2015, the Chinese government relaxed its “family planning policy” that had been implemented for over three decades, allowing each couple to have two children. In China, about 90 million women of childbearing age are eligible to have a second child. And an estimated 30% of them have the desire. Therefore, China’s fertility drug market is promising.

Topics Covered:
– Situation of infertility in China
– Overview of China’s fertility drug market
– Analysis on the fertility drug manufacturers in China
– Major factors influencing the development of fertility drugs in China
– Forecast on China’s Recombinant Human Lutropin alfa market from 2018 to 2022

The post Investigation Report on China’s Recombinant Human Lutropin alfa Market, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Mecobalamin Market, 2018-2022

admin — Thu, 13 Dec 2018 02:22:22 +0000

Description
Peripheral neuropathy is a syndrome caused by many factors.
Mecobalamin is a peripheral nerve repair agent. Mecobalamin tablets are used to treat peripheral neuropathy and diseases caused by vitamin B12 deficiency by repairing damaged nerves, relieving pain and numbness, and alleviating sensory disturbances and movement abnormalities. Mecobalamin injection can be used to treat megaloblastic anemia.
Developed by Eisai Co., Ltd., Mecobalamin (trade name: Methycobal) was launched in Japan in the mid-1980s and introduced to China in 1996. Since 2003, several Chinese pharmaceutical companies have launched generic Mecobalamin products. Mecobalamin has been developing rapidly since it entered China, with its annual sales value increasing from less than CNY 200 million in 2005 to about CNY 609 million in 2017. There is huge demand for Mecobalamin in China. China’s Mecobalamin market is dominated by Eisai China Inc., Eisai Co., Ltd., Jiangsu Sihuan Biopharmaceutical Co., Ltd., Nanjing Hailing Pharmaceutical Co., Ltd., North China Pharmaceutical Company Ltd., etc. In 2017, the market share by sales value of Eisai Co., Ltd. and its subsidiary Eisai China Inc. totaled about 70%.
It is expected that as the lifestyle changes and the population ages, and the incidences of peripheral neuropathy and megaloblastic anemia gradually increases, Mecobalamin will still have some growth potential in China.

Topics Covered:
– Indications for Mecobalamin
– Sales of Mecobalamin in China
– Competition on China’s Mecobalamin market
– Major Mecobalamin manufacturers in China
– Prices of Mecobalamin in China from 2017 to 2018
– Major factors influencing the development of China’s Mecobalamin market
– Prospect of China’s Mecobalamin market from 2018 to 2022

The post Investigation Report on China’s Mecobalamin Market, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Levofloxacin Market, 2018-2022

admin — Thu, 13 Dec 2018 02:22:20 +0000

Description
The antibacterial drug segment is the largest and most profitable segment of the global pharmaceuticals market. As antibacterial drugs that develop rapidly in recent years, quinolones are receiving more and more attention from all over the world. As a laevo isomer of Ofloxacin, Levofloxacin has the same antibacterial spectrum, double antibacterial effect, and lower toxicity. Currently, fluoroquinolones are second only to cephalosporins and penicillins on the antibacterial market. Levofloxacin, a third-generation fluoroquinolone, was developed by Daiichi Pharmaceutical Co., Ltd. (merged with Sankyo Co., Ltd. into “Daiichi Sankyo” in 2005) and first marketed in Japan in 1994. In 1995, Levofloxacin APIs and tablets manufactured by Daiichi Pharmaceutical Co., Ltd. were admitted to the Chinese market. After that, Daiichi Pharmaceutical Co., Ltd. established its Chinese subsidiary Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. with an investment of USD 50 million. The subsidiary produces Levofloxacin preparations in China with the APIs from its parent company. The Levofloxacin tablets produced in China were launched in 1996 under the trade name Cravit. At that time, the retail price was about 7 CNY/tablet. Effective and inexpensive, Cravit saw its sales value rising on the Chinese market. Later, some Chinese companies developed generic Levofloxacin, and extended the dosage forms from tablets to injections, capsules, gels, etc.
According to CRI’s market research, in 1998 when it had been launched in China for over one year, Levofloxacin became one of the top 100 drugs by sales value, and then showed an upward trend. The sales value of Levofloxacin declined from 2016 to 2017 after it reached CNY 1.23 billion in 2015. In 2017, China’s Levofloxacin market was dominated by Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd., Yangtze River Pharmaceutical (Group) Co., Ltd., China Resources Double-Crane Pharmaceutical Co., Ltd., Santen Pharmaceutical Co., Ltd., and Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory. By sales value, Daiichi Sankyo Pharmaceutical (Beijing) Co., Ltd. captured a market share of 29.1%. The injections, tablets, and eye drops accounted for about 63%, 20% and 13.7% respectively of China’s Levofloxacin market. The other dosage forms had a small market share.
As environmental pollution and population aging intensify in China, there will be higher incidences of the main indications for Levofloxacin, for example, respiratory infection, urinary infection and intestinal infection. It is expected that China’s Levofloxacin market will still have some growth potential from 2018 to 2022.

Topics Covered:

– Development environment of Levofloxacin in China

– Market size of Levofloxacin in China

– Competitive landscape of China’s Levofloxacin market

– Prices of Levofloxacin in China

– Prospect of China’s Levofloxacin market from 2018 to 2022

The post Investigation Report on China’s Levofloxacin Market, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Insulin Detemir Market, 2018-2022

admin — Thu, 13 Dec 2018 02:22:17 +0000

Description
In the past three decades, the incidence of diabetes kept rising in China with the aging population, changed dietary habits and reduced physical activities resulting from the rapid economic development. It is estimated that at the end of 2017, there were more than 100 million diabetic patients in China. Most of them are Type 2 diabetic patients. The increasing number of diabetic patients expands the market size of diabetes drugs in China.
Insulin analogs include quick-acting insulin analogs, long-acting insulin analogs and premixed insulin analogs. Long-acting insulin analogs include Insulin Glargine and Insulin Detemir. The Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2017 Edition) updated the instructional roadmap for the clinical treatment of diabetes from the use of first-line, second-line, third-line and fourth-line drugs to the use of a single drug, fixed dose combinations which combines two or three drugs, and insulin injections, which drove the growth of the insulin market.
Developed by Danish company Novo Nordisk with genetically engineered recombinant human insulin, Insulin Detemir is a new-type long-acting soluble insulin analog that avoids the common side effects of non-soluble insulin. In 2005, Novo Nordisk’s Insulin Detemir (trade name: Levemir) was launched in the U.S. In 2014, the global sales value of Levemir reached USD 2 billion. In 2017, it was USD 2.28 billion, about 17.7% lower than that in 2016. Levemir is a basal insulin with Insulin Detemir as the active pharmaceutical ingredient (API). The long-acting insulin analog has a mild and predictable effect, and is less likely to cause weight gain and nocturnal hypoglycemia. CRI’s market research shows that since 2009 when the drug was introduced to China, the sales value of Insulin Detemir has been rising. It increased from less than CNY 3 million in 2010 to more than CNY 100 million in 2017.
According to CRI, by the end of 2018, China’s Insulin Detemir is monopolized by Novo Nordisk. However, some Chinese companies is developing generic Insulin Detemir. For example, Tonghua Dongbao Pharmaceutical Co., Ltd. filed the CFDA with the drug registration applications for Insulin Detemir API and Insulin Detemir injection on Apr. 15, 2015, and obtained the clinical trial approvals for its Insulin Detemir API and Insulin Detemir injection on Oct. 20, 2017. Other companies have also applied for registering their Insulin Detemir API and Insulin Detemir injections but have not obtained the approvals yet. These companies include Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Zhuhai United Laboratories Co., Ltd. From 2020, the generic Insulin Detemir by Chinese pharmaceutical companies will be launched in succession.
It is expected that as the number of diabetic patients continues to grow, Insulin Detemir will still have huge market potential from 2018 to 2022.

Topics Covered:
– Situation of diabetes in China
– Sales of Insulin Detemir in China
– Prices of Insulin Detemir in China
– Progress of generic Insulin Detemir by Chinese enterprises
– Prospect of China’s Insulin Detemir market from 2018 to 2022

The post Investigation Report on China’s Insulin Detemir Market, 2018-2022 first appeared on CRI Report.

Research Report on Metal Mineral Import in China, 2019-2023

admin — Thu, 13 Dec 2018 02:22:14 +0000

Description
With the rapid development of economy and industry, China has become the most important industrial company in the world, and its demand for metal minerals are also growing. Because of insufficient reserves, low ore grades and high mining costs, China needs to import a large quantity of metal minerals every year. According to the data from China Customs, in 2017, copper ore, manganese ore, bauxite, chrome ore and zinc ore were the five metal minerals that had the highest import value except iron ore. Their import value all exceeded USD 2 billion.
According to CRI, in China, copper ore is the metal mineral whose import value is only second to that of iron ore. In 2017, China imported 17.35 million tons of copper ore with a total value up to USD 26.38 billion. The copper ore reserves in China are only about 4% of the global total. Therefore, China’s copper ore industry relies heavily on imports. From 2015 to 2017, the proportion of imported copper ore to copper ore consumption in China stayed above 88%. As the two biggest sources of China’s copper ore imports, in 2017, Peru and Chile contributed 28.40% and 26.57% respectively to the import volume of copper ore in China.
Manganese ore is a metal mineral with high import value in China. In 2017, China imported 21.26 million tons of manganese ore with a total value up to USD 4 billion. The manganese ore reserves in China are only about 7% of the global total. Therefore, China’s reliance on manganese ore imports stays above 80%. South Africa, Australia, Gabon, Ghana and Brazil are the major sources of China’s manganese ore imports. In 2017, the manganese ore imported from these countries totaled 19.05 million tons, accounting for about 90% of the total import volume of manganese ore in China.
Bauxite is also a metal mineral that has high import value in China. In 2017, its import value reached USD 3,445 million. Because of low unit price, the import volume was up to 68.55 million tons. From 2013 to 2017, China’s reliance on bauxite imports fluctuated between 40% and 60%. Guinea and Australia take up the majority of China’s bauxite import market. In 2017, their market share totaled about 77%.
Chrome ore is also a metal mineral that has high import value in China. China is a chrome ore poor country. In 2017, the national chrome ore reserves were far lower than the import volume of chrome ore. Therefore, China’s chrome ore industry is almost 100% reliant on imports. South Africa is the biggest source of China’s chrome ore imports. In 2017, the chrome ore imported from South Africa accounted for about 72.34% of China’s chrome ore imports.
Zinc ore is also a metal mineral with high import value in China. In 2017, its import value reached USD 2.25 billion, the highest level from 2013 to 2017. The zinc ore reserves in China total 41 million tons, ranking the third in the world. Therefore, China’s reliance on zin ore imports is low, fluctuating around 20% in most years. Australia, Peru and Russia are the three biggest sources of China’s zinc ore imports, contributing over 80% to the import volume of zinc ore in China.
It is expected that from 2019 to 2023, China will continue to import a large quantity of metal minerals such as copper ore, manganese ore, bauxite, chrome ore and zinc ore.

Topics Covered:
– Demand for metal minerals in China
– Import volume of metal minerals in China from 2013 to 2018
– Major sources of China’s metal mineral imports
– Major factors affecting metal mineral import in China
– Forecasts on metal mineral import in China from 2019 to 2023

The post Research Report on Metal Mineral Import in China, 2019-2023 first appeared on CRI Report.

Investigation Report on China’s Telmisartan Market, 2018-2022

admin — Thu, 13 Dec 2018 02:22:11 +0000

Description
By the end of 2017, there were about 330 million hypertensive patients in China, in another word, one in every three adults in China had hypertension. The incidence of hypertension in China rose from 5.1% in 1959 to 37.2% in 2017.
Angiotensin II receptor antagonists (angiotensin receptor blockers, ARBs) are antihypertensive drugs that has been growing rapidly since it emerged in the 1990s. As an important ARB administered orally once a day to treat essential hypertension,
Telmisartan was discovered by Boehringer Ingelheim and first launched in the U.S. as Micardis in 1999. In the same year, in Germany, it was launched by Boehringer Ingelheim and Glaxo Wellcome in the trades name of Micardis and Pritor respectively. Then it was marketed in several countries. The patent for Telmisartan expired in 2014.
At the end of 2000, Boehringer Ingelheim introduced the active pharmaceutical ingredient and preparations of Telmisartan to China. Telmisartan had developed fast since it entered in China. The sales value kept increasing before 2014 when it began to decrease, reaching about CNY 165 million in 2017. At present, China’s Telmisartan market is dominated by Boehringer Ingelheim, China Resources Double-Crane Pharmaceutical Co., Ltd., Yichang HEC Changjiang Pharmaceutical Co., Ltd., and Jiangsu Wanbang Biopharmaceuticals Co., Ltd. Boehringer Ingelheim has the largest market share. In 2017, its market share by sales value was about 72.4% but showed a downward trend. It is expected that with the increasing number of hypertensive patients, China’s Telmisartan market will still have some growth potential.

Topics Covered:
– Sales of Telmisartan in China
– Sales of Telmisartan in China by region
– Competitive landscape of China’s Telmisartan market
– Prices of Telmisartan in China
– Major factors affecting China’s Telmisartan market
– Prospect of China’s Telmisartan market

The post Investigation Report on China’s Telmisartan Market, 2018-2022 first appeared on CRI Report.

Investigation Report on China’s Recombinant Lispro Insulin Market, 2018-2022

admin — Thu, 13 Dec 2018 02:22:08 +0000

Description
According to CRI, the rapid development of China’s economy in the past 30 years has brought about changes in people’s lifestyles, for example, the reduction in exercise and the rising intake of calories, which increases the incidence of diabetes. It is estimated that by the end of 2017, the number of diabetic patients in China had exceeded 100 million. For patients with Type 1 diabetes, insulin is the only effective treatment. In addition, 30% to 40% of patients with Type 2 diabetes eventually become insulin dependent.
With the increasing number of diabetic patients, the market size of diabetes drugs in China is expanding. Third-generation insulin such as Insulin Glargine, Insulin Aspart and Insulin Lispro take up a large market share.
Recombinant Lispro Insulin is a new-type insulin analogue that takes effect more quickly, lasts for a shorter period and is more in line with the insulin secretion curve during physiological meals. Preparations Recombinant Lispro Insulin Injection, Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (25R), and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (50R) can all better control blood sugar and reduce hypoglycemia. Recombinant Lispro Insulin was developed by Lilly. Lilly’s Recombinant Lispro Insulin Injection (trade name: Humalog), Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (25R) (trade name: Humalog Mix25), and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (50R) (trade name: Humalog Mix50) were approved by the FDA for the treatment of diabetes between Apr. 1996 and Dec.1999, and launched in China in 2005, 2010 and 2008 respectively. By the end of 2018, in addition to Lilly’s Humalog, the only Recombinant Lispro Insulin products in China are domestic manufacturer Gan & Lee Pharmaceuticals’ Recombinant Lispro Insulin Injection and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (25R) that were launched in 2006 and 2014 respectively.
According to CRI, Recombinant Lispro Insulin has been developing rapidly since it entered China, with annual sales value increasing from less than CNY 7 million in 2005 to CNY 243 million in 2017. The only Recombinant Lispro Insulin manufacturers on the Chinese market are Lilly and Gan & Lee Pharmaceuticals. By sales value, the market share of Lilly’s Recombinant Lispro Insulin exceeded 98% in 2017 but is declining slowly. Optimistic about China’s Recombinant Lispro Insulin market, some other domestic pharmaceutical companies are stepping up the imitation of Recombinant Lispro Insulin. For example, in Oct. 2018, Tonghua Dongbao Pharmaceutical Co., Ltd. announced that the CFDA had approved the clinical trials of its Recombinant Lispro Insulin Injection, Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (25R), and Mixed Protamine Zinc Recombinant Human Insulin Lispro Injection (50R). It is expected that in the next few years, more Recombinant Lispro Insulin products by domestic pharmaceutical companies will be launched.
It is expected that as the number of diabetic patients continues to increase, China’s Recombinant Lispro Insulin market will still have some growth potential.

Topics Covered:
– Situation of diabetes and overview of the antidiabetic drug market in China
– Market size of Recombinant Lispro Insulin in China
– Major Recombinant Lispro Insulin manufacturers in China
– Prices of Recombinant Lispro Insulin in China
– Major factors affecting the development of China’s Recombinant Lispro Insulin market
– Prospect of China’s Recombinant Lispro Insulin market

The post Investigation Report on China’s Recombinant Lispro Insulin Market, 2018-2022 first appeared on CRI Report.